SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

22 Oct 2021 Evaluate
The Sales for the quarter ended September 2021 of Rs. 200.30 million declined by -97.37% from Rs. 7607.50 millions.Good  Net Profit growth of 40.64% reported above the corresponding previous quarter figure of Rs. 626.30 millions to Rs. 880.80 millioins.The company reported a degrowth in operating Profit to 1032.30 millions from 1320.30 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 200.30 7607.50 -97.37 402.90 15147.00 -97.34 27095.00 31399.00 -13.71
Other Income 1060.80 128.90 722.96 1101.90 218.70 403.84 478.80 1732.30 -72.36
PBIDT 1032.30 1320.30 -21.81 1103.50 2723.60 -59.48 4749.40 5441.40 -12.72
Interest 75.70 272.10 -72.18 146.80 669.30 -78.07 1018.00 1362.00 -25.26
PBDT 956.60 1048.20 -8.74 956.70 2054.30 -53.43 3731.40 4062.40 -8.15
Depreciation 15.40 295.90 -94.80 30.60 591.20 -94.82 999.70 1074.00 -6.92
PBT 941.20 752.30 25.11 926.10 1463.10 -36.70 2731.70 2988.40 -8.59
TAX 60.40 126.00 -52.06 56.60 316.40 -82.11 586.90 -223.00 -363.18
Deferred Tax -101.00 -4.80 2004.17 -101.00 -4.80 2004.17 0.00 0.00 0.00
PAT 880.80 626.30 40.64 869.50 1146.70 -24.17 2144.80 3211.40 -33.21
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 515.38 17.36 2869.58 273.89 17.98 1423.21 17.53 17.33 1.15

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×